Grant & Eisenhofer Boosts Antitrust Practice with Addition of Linda Nussbaum and John Radice

NEW YORK, Sept. 2 /PRNewswire/ -- Leading securities and corporate governance law firm, Grant & Eisenhofer P.A., today announced that it has expanded its Antitrust practice with the appointment of Linda P. Nussbaum as a Director and John D. Radice as a Senior Counsel.  They will be based in the firm's New York office.

"The top-level antitrust expertise that Linda and John bring to the firm significantly enhances the existing practice group and will be a tremendous asset to our clients," said Jay Eisenhofer, managing director and co-founder of Grant & Eisenhofer. 

Grant & Eisenhofer broadened its practice groups to include antitrust litigation in June of this year.  

"Together, Linda and John bring decades of successful experience in class and individual antitrust litigation, particularly in the pharmaceutical field," said Stuart Grant, the firm's managing director and co-founder. "As we continue to expand our complex litigation offerings, Linda and John are a terrific addition to our antitrust group."

Susan R. Schwaiger, an antitrust attorney with nearly two decades of experience, also will be joining the firm as associate.  Ms. Schwaiger previously was Of Counsel with several leading New York-based antitrust firms representing plaintiffs in class and individual actions.

Linda P. Nussbaum

Linda Nussbaum's practice focuses on plaintiff's antitrust litigation in both class and individual actions. Ms. Nussbaum has served as sole or co-lead counsel in many significant antitrust class actions which have resulted in substantial recoveries, many in the realm of hundreds of millions of dollars.  Ms. Nussbaum recently conducted a five-week jury trial on behalf of Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals in Boston before Justice Saris resulting in a RICO verdict against Pfizer of $47 million before trebling.

Ms. Nussbaum presently serves in a lead counsel position in:  In re Puerto Rican Cabotage Antitrust Litigation; In re DDAVP Direct Purchaser Antitrust Litigation; In re Wellbutrin XL Antitrust Litigation; Meijer, Inc., et al. v. Astrazeneca Pharmaceuticals Lp, et al (Torprol Direct Purchaser Antitrust Litigation); In re Miralax Direct Purchaser Antitrust Litigation and Meijer, Inc., et al. v. Abbott Laboratories (Norvir Direct Purchaser Antitrust Litigation).  In addition, Ms. Nussbaum represents large corporate entities in individual actions in In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation; In re Neurontin Marketing and Sales Practices Litigation; In re Chocolate Confectionary Antitrust Litigation; and CVS Pharmacy v. American Express Travel Related Services, et al.

Ms. Nussbaum is admitted to practice in New York and DC, as well as various district courts and the Supreme Court of the United States.  Ms. Nussbaum earned her law degree from George Washington University in 1977 and her LL.M in Taxation from New York University School of Law in 1984.  She graduated with honors from Brooklyn College in 1974.  

John D. Radice

John D. Radice practices in the areas of antitrust, False Claims Act, and other areas of complex civil litigation.  Representative cases include: In re Tricor Direct Purchaser Antitrust Litig., In re Neurontin Marketing & Sales Litig., United States ex rel. Piacentile v. Bristol-Myers Squibb Co., United States ex rel. Marchese v. Cell Therapeutics, Inc.,.  Prior to joining the firm, Mr. Radice was associated with major plaintiffs' class action firms in New York and Philadelphia, where he primarily represented clients pursuing antitrust, False Claims Act, and international human rights cases.

Mr. Radice is admitted to practice in New York and New Jersey, as well as various district courts.  Mr. Radice clerked for Judge Edith Brown Clement in the United States Court of Appeals for the Fifth Circuit in New Orleans following his graduation from New York University School of Law in 2003. He graduated magna cum laude from Princeton University in 1997.

Note:  In addition to its antitrust practice, Grant & Eisenhofer P.A. represents institutional investors, both domestic and foreign,  in securities class actions, corporate governance actions and derivative litigation.  The firm has recovered approximately $12 billion for shareholders in the last five years and was cited by RiskMetrics for securing the highest average investor recovery in securities class actions of any U.S. law firm in 2008.  Grant & Eisenhofer has also been named one of the country's top plaintiffs' law firms by the National Law Journal for the past four years.  For more information, visit www.gelaw.com

SOURCE Grant & Eisenhofer P.A.